Research Article of American Journal of Cardiology Research and Reviews
Chemotherapy-induced cardiotoxicity: Preliminary report from a tertiary cancer centre in India
Dr Suwarna Tambade MBBS, DNB- Medicine,
Dr Sagar Bhalerao MBBS MD Oncology,
Dr Rucha Sule MBBS, MD Psychiatry
Dr Rajnish Nagarkar MS, MRCS (Edin), DNB BSS (UK), MNAMS
HCG Manavata Cancer Centre, Nashik, India.
Cancer has emerged as a major public health issue in India owing to significant epidemiological and demographic transition. As per literature, the overall ten-year survival rate for cancer is at 50% across the 20 most common malignancies. However, the ten-year survival rate is even more high, i.e. approximately 80% or higher for breast, melanoma, lymphoma, and uterine cancers. Contrary to the improved long-term cancer survival rates there has been an increase in adverse cardiac effects of cancer treatment. A retrospective analysis of patients admitted at HCG Manavata Cancer Centre, Nashik was conducted. The study was conducted at a single center comprising of 115 participants. Anthracyline chemotherapy has remained a mainstay treatment approach for cancer patients. Cardiotoxic side-effects of anthracyline chemotherapy regimens often limits their dosing. Although anthracylines have been associated with improved cancer outcomes, there remains an increased risk of cardiovascular morbidity and mortality. Doxorubicin-induced cardio toxicity was 5.45% while trastuzumab cardio toxicity was 5.26% (Table 4). The estimated cardio toxicity rate for our two-year follow-up was 4.08% for all specified chemotherapy regimens. The early detection of cardio toxicity by appropriate follow-up and monitoring is essential. Evaluation of patients using LVEF as a key parameter would help prevent irreversible cardio toxic events. Our preliminary report may act as a base for researchers and academicians to conduct and review ongoing chemotherapy regimens.
Keywords: Chemotherapy-induced cardiotoxicity, Preliminary report, Tertiary cancer centre, India
How to cite this article:
Suwarna Tambade, Sagar Bhalerao, Rucha Sule, Rajnish Nagarkar. Chemotherapy-induced cardiotoxicity: Preliminary report from a tertiary cancer centre in India.American Journal of Cardiology Research and Reviews, 2018, 1:7. DOI:10.28933/ajcrar-2018-10-0501
1. Rajpal S, Kumar A, & Joe W. Economic burden of cancer in India: Evidence from cross-sectional nationally representative household survey, 2014. PLoS ONE, 2018;13(2), e0193320.
2. McGowan, J. V., Chung R., Maulik A, Piotrowska I, Walker J. M, & Yellon D. M. Anthracycline Chemotherapy and Cardiotoxicity. Cardiovascular Drugs and Therapy, 2017;31(1), 63–75.
3. Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337.
4. Spallarossa P, Maurea N, Cadeddu C, Madonna R, Mele D, Monte I. A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e84-e92
5. Reinbolt, RE, Patel R, Pan X, Timmers CD, Pilarski R, Shapiro CL. Et al. Risk factors for anthracycline-associated cardiotoxicity. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2016;24(5):2173-2180.
6. Tan TC, Scherrer-Crosbie M. Assessing the Cardiac Toxicity of Chemotherapeutic Agents: Role of Echocardiography. Current cardiovascular imaging reports. 2012;5(6):403-409.
7. McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline Chemotherapy and Cardiotoxicity. Cardiovascular Drugs and Therapy. 2017;31(1):63-75. doi:10.1007/s10557-016-6711-0.
8. Hamirani Y, Fanous I, M. Kramer C, Won A, Salerno M, Dillon P. Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study. Medical oncology (Northwood, London, England). 2016;33(7):82. doi:10.1007/s12032-016-0797-x.
9. Volkova M, Russell R. Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment. Current Cardiology Reviews. 2011;7(4):214-220. doi:10.2174/157340311799960645.
10. Tan L-L, Lyon AR. Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment. Current Treatment Options in Cardiovascular Medicine. 2018;20(7):55. doi:10.1007/s11936-018-0641-z.
11. Haybar H, Jalali MT, Zibara K, Zayeri ZD. Mechanisms and biomarkers to detect chemotherapy-induced cardiotoxicity. Clin Cancer Investig J 2017;6:207-13